SlideShare una empresa de Scribd logo
1 de 25
Descargar para leer sin conexión
Identify the Key Players and Their
Regulators in Major Cancer Types

Jesse Liang, Ph.D.

1
Sample & Assay Technologies
8 Hallmarks of Cancer

.

.

.

.

.

.

.

.

.

The 8 Hallmarks of Cancer (Cell, March 2011):
1. Sustaining proliferative signaling
2. Evading growth suppressors
3. Resisting cell death
4. Enabling replicative immortality
5. Inducing angiogenesis
6. Activating invasion and metastasis
7. Reprogramming energy metabolism
8. Escaping immune destruction

-2-

Sample & Assay Technologies
Corresponding PCR Arrays to Study These Hallmarks
1. Cell Cycle
2. Apoptosis
3. Cell Death Pathway Finder
4. Telomeres and Telomerases
5. Angiogenesis
6. Extracellular Matrix (ECM) and Adhesion Molecules
7. EMT (Epithelial-Mesenchymal Transition)
8. Tumor Metastasis
9. Cell Motility
10. Energy Metabolism
11. Innate and Adaptive Immune Response
12. Cancer Pathway Finder

.

.

.

.

.

.

.

.

.

.

.

.

.

http://www.sabiosciences.com/ArrayList.php
-3-

Sample & Assay Technologies
Profile Key Gene Expressions –

Using RT2 Profiler PCR Array

84 Pathway-Specific
Genes of Interest
5 Housekeeping Genes
Genomic DNA
Contamination Control
Reverse Transcription
Controls (RTC)
Positive PCR Controls
(PPC)

-4-

Sample & Assay Technologies
Simple Workflow of PCR Arrays
cDNA Synthesis (kit)
45 minutes
Load Plates (Use 8-Channel
Pipettors)
2 minutes

Run 40 cycle qPCR Program
2 to 2.5 hours
compatible with all major
real-time PCR instruments

Upload and Analyze Data
15 minutes

-5-

Sample & Assay Technologies
Identify the Key Genetic Players in Breast Cancer

.

Breast Cancer PCR Array

http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-131A.html
Breast cancer can be classified into normal breast-like, luminal, HER2-like, and basallike (also inaccurately called triple-negative) tumors.

.

Tumor Classification Markers:
Luminal: ESR1 (ERa), FOXA1, GATA3, KRT8, KRT18, SLC39A6, TFF3, XBP1.
HER2-like: ERBB2 (HER2), GRB7.
Basal-like / Triple Negative: BIRC5, EGFR, KRT5, NOTCH1.
Metastasis to Lung: ID1, MMP2 (Gelatinase A), PTGS2 (COX2).
.

Signal Transduction:
Steroid Receptor-Mediated: AR, BRCA1, CCNE1, CTNNB1, ESR1 (ERa), ESR2 (ERß),
IGF1, KRT19, PGR, RB1.
Hedgehog: BCL2, CCND1, GLI1, SNAI2.
Glucocorticoid: IGFBP3, NME1 (NM23A), NR3C1 (GRL).
Classical WNT: APC, CCND1, CTNNB1, SFRP1.
PI3K/AKT: AKT1, ERBB2 (HER2), IGF1, IGF1R, PTEN.
NOTCH: BIRC5, NOTCH1.
MAPK: MAPK1 (ERK2), MAPK3 (ERK1), MAPK8 (JNK1), TP73.
.

-6-

Sample & Assay Technologies
Breast Cancer Subtypes

Subtype

These tumors tend to be

Prevalence

Luminal A

ER+ and/or PR+, HER2-, low Ki67

42-59%

Luminal B

ER+ and/or PR+, HER2+ (or HER2with high Ki67)

6-19%

Triple
negative/basal-like

ER-, PR-, HER2-, cytokeratin 5/6 +
and/or HER1(EGFR)+

14-20%

HER2+

ER-, PR-, HER2+

7-12%

-7-

Sample & Assay Technologies
Identify the Key Genetic Players in Lung Cancer

.

Lung Cancer PCR Array

http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-134A.html
non-small-cell lung carcinoma (NSCLC) and small-cell lung carcinoma (SCLC)

.

Differentially Methylated Promoters: APBA1, APC, CADM1, CDH1, CDH13, CDKN1C,
CDKN2A, CDKN2B, CXCL12, CYP1B1, DLC1, FHIT, MGMT, MLH1, MTHFR, OPCML,
PRDM2, RASSF1, RASSF2, SFRP1, TCF21
Metastatic Potential: ANXA5, DUSP6, ERBB3, HGF, HMMR, IRF4, LCK, MET, MMD, NF1,
STAT1, STAT2
.

.

Differentially Expressed Genes in Adenocarcinoma (AC) Versus Squamous Cell
Carcinoma (SCC):
Higher in AC than in SCC: CLCA2, DSG3, KRT5, KRT14, SPRR1A
Higher in SCC than in AC: AGR2, LGSN, NKX2-1, SFTA3, SPINK1
.

.

Up-Regulated in Lung Cancer: CEACAM5, COL11A1, CP, CXCL13, GREM1, MKI67,
MMP1, MMP12, SPINK1, SPP1, TOP2A, TOX3
Down-Regulated in Lung Cancer: AGER, CA4, CLDN18, CLIC5, FABP4, GPM6A,
SCGB1A1, SFTPC, SOSTDC1, WIF1
.

.

-8-

Sample & Assay Technologies
Identify the Key Genetic Players in Prostate Cancer

.

Prostate Cancer PCR Array

http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-135A.html

.

Differentially Methylated Promoters: APC, AR, CAV1, CCNA1, CDH1, CDKN2A, DKK3,
DLC1, EDNRB, GPX3, GSTP1, MGMT, MSX1, PDLIM4, PTGS2, RARB, RASSF1, SFRP1,
SLC5A8, TIMP2, TNFRSF10D, ZNF185

.

Up-Regulated in Prostate Cancer: ARNTL, CAMSAP1, DDX11, ECT2, ETV1, HAL,
IGFBP5, KLK3, MTO1, PDPK1, RBM39, SOCS3, SOX4, SUPT7L

.

Down-Regulated in Prostate Cancer: CCND2, CLN3, GCA, IGF1, LGALS4, LOXL1,
PPP2R1B, SFRP1, SLC5A8, TFPI2, USP5

.

Metastatic Potential: CREB1, INTS6, KLHL13, MAX, NDRG3, PES1, SEPT7, SCAF11

.

Androgen Signaling: AR, CAV1, CCND1, DAXX, EGFR, FOXO1, GNRH1, IGF1, IL6,
NFKB1, NRIP1, PTEN, SHBG, TGFB1I1, TIMP2, TIMP3, VEGFA
.

-9-

Sample & Assay Technologies
Identify the Key Genetic Players in Liver Cancer

.

Liver Cancer (HCC) PCR Array

http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-133A.html

.

Genes Up-Regulated During HCC: BCL2, BIRC5, CCND1, CFLAR (CASPER), FZD7, IGF2, IRS1, LEF1,
MCL1, MET, NFKB1, PIN1, PTK2, RAC1, RHOA, SMAD7, STAT3, TCF4, TGFA, TGFB1, TNFSF10
(TRAIL), XIAP
.

Genes Down-Regulated During HCC: BAX, BID, CASP8 (FLICE), CDKN1A (p21CIP1/WAF1), CDKN2A
(p16INK4), DLC1, FADD, FAS (TNFRSF6), HHIP, IGFBP1, IGFBP3, ITGB1, PTEN, RB1, SMAD4, SOCS1,
SOCS3,TGFBR2, TNFRSF10B (DR5)
.

Signal Transduction:
Classical WNT: CCND1, CDKN2A (p16INK4), CTNNB1, FZD7, LEF1, MTDH, PIN1, RB1, SFRP2, TCF4.
TGFß: SMAD4, SMAD7, TGFB1, TGFBR2
PI3K/AKT: AKT1, IRS1, PTEN.
IGF/IGFR: IGF2, IGFBP1, IGFBP3, IRS1
Hippo: YAP1 (Yes-Associated Protein (YAP) is a potent oncogenic driver and an
.

independent prognostic risk factor of HCC)
Ras/Raf/MEK/ERK: CDKN1A (p21CIP1/WAF1), CDKN2A (p16INK4), DLC1, HRAS, NRAS, RAC1,
RASSF1, RB1, RHOA, TP53
EGFR: ADAM17 (CD156B), CDH13, EGF, EGFR, TGFA, TGFB1
MET/HGF: MET, HGF
Small GTPase-Mediated: CDH13, CDKN1A (p21CIP1/WAF1), CDKN2A (p16INK4), DAB2IP, DLC1,
HRAS, NRAS, RAC1, RASSF1, RB1, RELN, RHOA, TP53

- 10 -

Sample & Assay Technologies
Identify the Key Genetic Players in Leukemia

.

Leukemia PCR Array

http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-137A.html
Clinical and pathological subtypes of leukemia define both its onset (acute or chronic)
and the affected blood cell type (lymphoblastic/lymphocytic or myeloid/myelogenous).

.

.

Differentially Methylated Promoters: APAF1, CADM1, CDH1, CDH13, CDKN1A, CDKN1B, CDKN1C,
CDKN2B, DAPK1, DKK3, DLC1, EGR3, HIC1, JUNB, MEIS1, MLH1, NPM1, PTEN, SFRP2, SFRP4,
SFRP5, SOCS1, TP53, WIF1
BCR-ABL Pathway: ABL1, BCR, GRB2, JAK2, SHC1, STAT3, STAT5A, STAT5B
JAK-STAT Signaling: AKT1, CSF3, IFNA1, IL4, IL6, JAK2, STAT1, STAT3, STAT5A, STAT5B, SOCS1
Hemopoiesis: BCL2, CSF3, CTNNB1, IL4, JAK2, LMO2, PML, RUNX1, STAT5A, STAT5B, TAL1, TP53
Myeloid Cell Differentiation: CTNNB1, FOXO3, IL4, JUN, LMO2, RUNX1, SPI1, STAT5A, STAT5B, TAL1
Immune System Development: BCL2, CSF3, CTNNB1, IL4, JAK2, LMO2, MLH1, PML, RUNX1,
STAT5A, STAT5B, TAL1, TLX1, TP53
Lymphocyte Proliferation/Differentiation: BCL2, CSF3, CTNNB1, IL4, IL6, STAT5A, STAT5B
Cytokines & Chemokines: CCL3, CSF3, CXCL10, IFNA1, IL1R1, IL4, IL6, IL8, IL10, IL12A
Malignancy: BAALC, BMPR1B, BTG3, CD34, CDC42EP3, CTGF, GAS2L3, MN1, NR4A3, RGS12
Leukemia Therapeutic Targets: AKT1, ALOX5, BCL2, CTNNB1, FGR, FOXO3, HCK, HDAC1,
HSP90AA1, IFNA1, JAK2, MCL1, MERTK, MTOR, PML, PRKCB, RAC2, SMO
Leukemia Stem Cell Transcriptional Regulators: CEBPB, GATA1, IKZF3, JUN, LMO1, LMO2, LYL1,
MEIS1, NFKB1, RUNX1, RUNX2, RUNX3, SPI1, STAT1, STAT3, STAT5A, TAL1, TLX1, TLX3
.

.

.

.

.

.

.

.

.

.

.

- 11 -

Sample & Assay Technologies
Identify the Key Genetic Players in Lymphoma
Lymphoma PCR Array
.

.

.

.

.

.

.

.

.

.

.

.

.

http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-139A.html
Differentially Methylated Promoters: AFF1, ATM, CADM1, CCND1, CDH1, CDH13, CDKN1C,
CDKN2B, CDKN2C, DAPK1, DLC1, FHIT, GSTP1, HIC1, HRK, ID4, LRP1B, MLH1, MYOD1, RASSF1,
RBP1, SLC19A1, TIMP2, TIMP3
DLBCL (Diffuse Large B-cell Lymphoma) Survival: ASB13, BCL6, ITPKB, LMO2, LRMP, MYBL1,
PAG1, PTK2, TTC9, VGLL4
Follicular Lymphoma Survival: C1QA, C4A, CCR1, F8, FCGR1A, FLT3LG, STAT4, TLR5,
TNFRSF1B, TNFSF13B
Lymphoma Therapeutic Targets: BCL6, BIRC5, BTK, CD22, CD40, CD80, CXCR4, FCGR1A,
HSP90AA1, MCL1, MS4A1, MTOR, NOTCH1, PARP1, PTK2, SRC, SYK, TGFB1, TNFSF13B
Inflammatory Response: C1QA, C4A, CCR1, CD40, CD40LG, CSF3, CXCR4, F8, IL6, NFKB1,
TGFB1, TLR5, TNF, TNFRSF1B
Immune System Process: BCL6, C1QA, C4A, CADM1, CD2, CD4, CD40, CD5, CD79A, CD80,
FCER2, IFNG, IL2, IL6, ITPKB, PDLIM7, PTPRC, SYK, TGFB1, TNFSF13B
T Cell Differentiation: BCL2, CD3D, CD4, CD8A, ITPKB, IL2, PTPRC, SYK, TGFB1, TP53
Cell Adhesion: BCL2, CADM1, CCR1, CD2, CD22, CD34, CD4, CD40LG, CD8A, CDH1, CDH13,
DLC1, F8, IL2, NCAM1, PTPRC, SRC, SYK, TNF
Cell Cycle: ATM, BCL2, BIRC5, CCND1, CDKN1C, CDKN2B, CDKN2C, ID4, IFNG, MKI67, MLH1,
MYC, RASSF1, TGFB1, TP53
PI3K/AKT Signaling: ALK, BCL2, BTK, CCND1, CCR1, CD2, CD4, CD40, CD40LG, CSF3, CXCR4,
HSP90AA1, IL2, IL6, MTOR, PTK2, SYK, TGFB1, TIMP2, TIMP3, TNFRSF1B, TNFSF13B, TP53
Gene Fusion: ALK, MME
DNA Repair: DNTT

- 12 -

Sample & Assay Technologies
Methylation PCR Arrays

.

.

1. DNA Digestion
Genomic DNA sample is aliquoted into four equal portions:

a. Mock Digest (Mo)
No enzymes are added in this reaction. The product of the mock digestion
represents the total amount of input DNA for real-time PCR detection.
b. Methylation Sensitive Digest (Ms)
Cleavage with a methylation-sensitive enzyme will digest unmethylated and
partially methylated DNA. The remaining (hyper)-methylated DNA will be
detected by real-time PCR.
c. Methylation Dependent Digest (Md)
Cleavage with a methylation-dependent enzyme will preferentially digest
methylated DNA. The remaining unmethylated DNA will be detected by realtime PCR.
d. Double Digest (Msd)
Both enzymes are added in the double digest, and all DNA molecules (both
methylated and unmethylated) will be digested. This reaction measures the
background and the fraction of input DNA refractory to enzyme digestion.
.

.

.

.

.

.

.

.

.

.

.

.

2. Real-Time PCR
3. Data Analysis
We provide user-friendly free online data analysis tool.

- 13 -

Sample & Assay Technologies
What Methylation PCR Array Offers – a Quick Screening Tool

.

What Does Methylation PCR Array Offer?

http://www.sabiosciences.com/dna_methylation.php

.

.

Disease or Pathway Focused: Simultaneously detect DNA

methylation of 24-96 genes on a 96-well or 384-well plate.

.

Genome-Wide Coverage: DNA methylation analysis of any human,

mouse or rat genes. You can also order individual primers for an individual
gene. Ordering custom array is also welcome.
.

Easy, Fast & Reliable: Simple restriction enzyme digestion followed

by optimized qPCR. No bisulfite conversion, cloning or sequencing.

- 14 -

Sample & Assay Technologies
Identify the Key Epigenetic Players in Breast Cancer
Breast Cancer Methylation PCR Array:
http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-011A.html
Cell Cycle, Growth, Differentiation & Development: BRCA1, CCNA1, CCND2, CDKN1C,
CDKN2A (p14ARF), CDKN2A (p16), SFN (14-3-3 sigma), TP73
Cell Adhesion: CDH1, CDH13
Transcription Factors: CDKN2A (p14ARF), ESR1, HIC1, PRDM2, RASSF1, TP73
Hormone Receptors: ESR1
Drug Metabolism: GSTP1
Apoptosis & Anti-Apoptosis:
CDKN2A (p14ARF), CDKN2A (p16), PYCARD, TNFRSF10C, TNFRSF10D, TP73
DNA Methylation: MGMT, PRDM2
Phosphatases: PTEN
Prostaglandin-Endoperoxide Synthase: PTGS2
Extracellular Matrix Molecules: ADAM23, SLIT2, THBS1
Proteases & Protease Inhibitors: DAM23, THBS1
Ras Associated Protein Superfamily: RASSF1

- 15 -

Sample & Assay Technologies
Identify the Key Epigenetic Players in Lung Cancer
Lung Cancer Methylation PCR Array:
http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-041A.html

.

Apoptosis & Anti-Apoptosis: APC, CADM1 (TSLC1), CDKN1C (p57Kip2), CDKN2A (p14ARF), CDKN2B
(p15INK4b), FHIT
Cell Adhesion & Migration: APC, CADM1 (TSLC1), CDH1, CDH13, DLC1, OPCML (aOBCAM)
Cell Cycle, Growth, Differentiation & Development: APC, CADM1 (TSLC1), CDKN1C (p57Kip2),
CDKN2A (p14ARF), CDKN2B (p15INK4b), DLC1, FHIT, MLH1, PRDM2 (RIZ1), RASSF1, RASSF2, TCF21
Chemokine: CXCL12
Neuronal Adaptor Protein: APBA1 (MINT1)
DNA Damage Repair: APC, MLH1, RASSF1
DNA Methyl Transferase: MGMT (AGT), PRDM2
Drug Metabolism: CYP1B1
Oncogene: PAX5
Histidine Triad Gene Family: FHIT
miRNA Genes: has-let-7a, hsa-miR-124
One Carbon Unit Metabolism: MTHFR
Transcription Factors: PAX5, PRDM2 (RIZ1), TCF21
Tumor Suppressor Gene Candidates: APC, CDKN1C (p57Kip2), CDKN2A (p14ARF), CDKN2B
(p15INK4b), MLH1, RASSF1, RASSF2
WNT Signaling: APC, SFRP1
.

.

- 16 -

Sample & Assay Technologies
Identify the Key Epigenetic Players in Prostate Cancer
Prostate Cancer Methylation PCR Array:
http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-051A.html

.

Apoptosis & Anti-Apoptosis: APC, CDKN2A (P16), TNFRSF10D
Calcium Channel Signaling: EDNRB
Caveolae Protein: CAV1
Cell Cycle, Growth, Differentiation & Development: APC, CCNA1, CDKN2A (P16), DLC1, RARB,
RASSF1
Cell Adhesion & Migration: APC, CDH1, DLC1, OPCML (aOBCAM), TIMP2
Cytokine: TNFRSF10D
Drug Metabolism: GPX3, GSTP1, SLC5A8
DNA Methyltransferase: MGMT (AGT)
Extracellular Matrix Remodeling: TIMP2
Inflammation: PTGS2 (COX2)
miRNA Genes: hsa-miR-34a
Mitogenesis: PTGS2 (COX2)
Nuclear Receptors: AR, RARB
Oncogene: CAV1
Protease Inhibitor: TIMP2
Retinoid Acid Signaling: RARB
Solute Carrier Family: SLC5A8
Transcription Factors and Cofactors: MSX1, PDLIM4 (RIL)
Tumor Suppressor Gene Candidates: APC, CAV1, CDKN2A (P16), RASSF1, SLC5A8, ZNF185
Wnt Signaling Pathway: APC, DKK3, SFRP1
.

- 17 -

Sample & Assay Technologies
Identify the Key Epigenetic Players in Liver Cancer
Liver Cancer Methylation PCR Array:

.

http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-031A.html

.

Angiogenesis: EP300
Apoptosis & Anti-Apoptosis: CDKN1B, CDKN2A (P16,), FHIT, PYCARD (TMS1/ASC), TNFRSF10D
Cell Adhesion & Migration: CDH1, DLC1, OPCML (aOBCAM), RELN
Cell Cycle, Growth, Differentiation & Development: CCND2 (Cyclin D2), CDKN1A, CDKN1B (p27KIP1),
CDKN2A (P16), DLC1, EP300, FHIT, RASSF1, WT1
Cytokine Receptor: TNFRSF10D
Cytokine Signaling Inhibitor: SOCS1
DNA Damage Repair: CDKN1A, MSH2, MSH3, RASSF1
Drug Metabolism: GSTP1
Extracellular Matrix Remodeling: RELN
GTPase-Activating Protein: DAB2IP
Histidine Triad Gene Family: FHIT
Inflammation: PYCARD (TMS1/ASC)
miRNA Gene: hsa-miR-1
Oncogene: E2F1
Transcription Factors: E2F1, EP300, RUNX3, WT1, EP300
Tumor Suppressor Gene Candidates: DLEC1, CDKN1A, CDKN2A (P16), E2F1, MSH2, MSH3,
RASSF1, RUNX3
Wnt Signaling Pathway: SFRP2
.

- 18 -

Sample & Assay Technologies
Identify the Key Epigenetic Players in Leukemia & Lymphoma
Leukemia & Lymphoma Methylation PCR Array:

.

http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-071A.html

.

Development & Differentiation: HCK, MAFB, MEN1, TP53
Cell Cycle: JUNB, MEN1, NPM1, TP53
DNA Damage & Repair: FANCC, FANCL, NPM1, PMS1, TP53
Extracellular Matrix and Adhesion: CD9, CTNNA1, SPOCK2
Growth & Proliferation: DRD2, MEN1, NPM1, SLC5A8, TP53
Signal Transduction: DRD2, EXT1, MEN1, NFATC1, NPM1, PARK2, PER2, TLE1, TP53
Transcription Factors & Co-Factors: AFF1, CEBPD, HOXA7, HOXB5, JUNB, MAFB,
NFATC1, NPM1, TLE1, TP53
Other: LMNA

.

.

.

.

.

.

.

.

- 19 -

Sample & Assay Technologies
Identify the Key Epigenetic Players in Other Cancers
Colon Cancer:

.

http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-061A.html

.

Gastric Cancer:

.

http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-021A.html

.

Melanoma:

.

http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-081A.html
--------------------------------------------------------------------------------------------------------------

.

.

EMT (Epithelial-Mesenchymal Transition):

.

http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-901A.html

.

Tumor Suppressor Genes:

.

http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-551A.html

.

Apoptosis:

.

http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-121A.html

.

Cell Cycle:

.

http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-201A.html

.

DNA Repair:

.

http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-421A.html

.

Cancer miRNA:

.

http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-591A.html

.

- 20 -

Sample & Assay Technologies
Important Note

.

Please Note:

If you study lung cancer, for example, I greatly recommend
that you use regular Lung Cancer PCR Array and Methylation
Lung Cancer PCR Array to get corresponding results. This
applies to other cancer types, also to apoptosis, cell cycle,
DNA damage, EMT, tumor suppressors, and cancer-related
miRNAs researchers.
.

- 21 -

Sample & Assay Technologies
Cancer Mutation PCR Arrays and Assays
Custom available!

We also provide over 900 individual gene assays:
http://www.sabiosciences.com/mutationproductlist.php?tab=browsebygene

- 22 -

Sample & Assay Technologies
Overview 45-Signaling Pathway Activity in a Cell Assay
Transcription factor activity can be used as a readout for the activation status of signal
transduction pathways. Therefore, the development of reliable cell-based assays to
measure transcription factor activity is a crucial technology for fast and efficient global
functional genomics and chemical genetics studies.

.

.

Cignal 45-Pathway Reporter Array is a novel cell-based assay for monitoring 45 cell
signaling pathways in cultured cells in a single experiment. You can observe
phenotypes and quantitate as a dual-luciferase assay.

http://www.sabiosciences.com/reporter_assay_product/HTML/CCA-901L.html
For individual assay: http://www.sabiosciences.com/reporterproductList.php
- 23 -

Sample & Assay Technologies
We Provide Service – Send Samples to Us & Receive Results!
Whole Genome
Illumina Gene Expression Profiling
Illumina Genotyping

.

Pathway / Focused Panel
Mutation Profiling
Methylation
PCR Array
miRNA PCR Array

.

.

.

.

.

Individual Gene / Locus
Mutation Detection
Methylation
qPCR

.

.

.

.

Sample Preparation – DNA, RNA Extraction and Purification
Cells, Tissue or Biofluids
Fixed Tissue
Small Sample

.

.

.

.

http://www.sabiosciences.com/servicecore.php

.

- 24 -

Sample & Assay Technologies
Contact Information

.

.

.

.

.

Jesse Liang
Email: jesse.liang@qiagen.com
Technical Support: 1-888-503-3187
Email: support@sabiosciences.com
Check Webinar Calendar:

http://www.sabiosciences.com/seminarlist.php

.

- 25 -

Sample & Assay Technologies

Más contenido relacionado

La actualidad más candente

Artesunate improves drug resistance of lung carcinomas via regulation of mi r...
Artesunate improves drug resistance of lung carcinomas via regulation of mi r...Artesunate improves drug resistance of lung carcinomas via regulation of mi r...
Artesunate improves drug resistance of lung carcinomas via regulation of mi r...Clinical Surgery Research Communications
 
A review of micro rn as related to the occurrence, diagnosis, and prognosis o...
A review of micro rn as related to the occurrence, diagnosis, and prognosis o...A review of micro rn as related to the occurrence, diagnosis, and prognosis o...
A review of micro rn as related to the occurrence, diagnosis, and prognosis o...Clinical Surgery Research Communications
 
Lnc rna neat1 is involved in temozolomide resistance by regulating mgmt in gl...
Lnc rna neat1 is involved in temozolomide resistance by regulating mgmt in gl...Lnc rna neat1 is involved in temozolomide resistance by regulating mgmt in gl...
Lnc rna neat1 is involved in temozolomide resistance by regulating mgmt in gl...Clinical Surgery Research Communications
 
Resveratrol induces apoptosis, autophagy and endoplasmic reticulum stress in ...
Resveratrol induces apoptosis, autophagy and endoplasmic reticulum stress in ...Resveratrol induces apoptosis, autophagy and endoplasmic reticulum stress in ...
Resveratrol induces apoptosis, autophagy and endoplasmic reticulum stress in ...Clinical Surgery Research Communications
 
Roles of circular rn as and their interactions with micro rnas in human disor...
Roles of circular rn as and their interactions with micro rnas in human disor...Roles of circular rn as and their interactions with micro rnas in human disor...
Roles of circular rn as and their interactions with micro rnas in human disor...Clinical Surgery Research Communications
 
ESMO 2020 Abstract Analysis - BioTrack
ESMO 2020 Abstract Analysis - BioTrack ESMO 2020 Abstract Analysis - BioTrack
ESMO 2020 Abstract Analysis - BioTrack Pranay Madan
 
Io combos and the big stick
Io combos and the big stick Io combos and the big stick
Io combos and the big stick Paul D. Rennert
 
Mantle Cell Lymphoma: from bench to clinic
Mantle Cell Lymphoma: from bench to clinicMantle Cell Lymphoma: from bench to clinic
Mantle Cell Lymphoma: from bench to clinicspa718
 
FISH IN MYELOMA
 FISH IN MYELOMA FISH IN MYELOMA
FISH IN MYELOMAspa718
 
CAR-T CELLS IN SOLID TUMORS
CAR-T CELLS IN SOLID TUMORSCAR-T CELLS IN SOLID TUMORS
CAR-T CELLS IN SOLID TUMORSClaire Roudot
 
Next-generation Sequencing in Acute Myeloid Leukemia
Next-generation Sequencing in Acute Myeloid LeukemiaNext-generation Sequencing in Acute Myeloid Leukemia
Next-generation Sequencing in Acute Myeloid Leukemiaasclepiuspdfs
 
Epigenetic regulation of cardiogenesis
Epigenetic regulation of cardiogenesisEpigenetic regulation of cardiogenesis
Epigenetic regulation of cardiogenesisPasteur_Tunis
 
Mi r 449b inhibits the migration and invasion of colorectal cancer cells thro...
Mi r 449b inhibits the migration and invasion of colorectal cancer cells thro...Mi r 449b inhibits the migration and invasion of colorectal cancer cells thro...
Mi r 449b inhibits the migration and invasion of colorectal cancer cells thro...Clinical Surgery Research Communications
 
ALETA CNS metastasis program 8 July 2020
ALETA CNS metastasis program 8 July 2020ALETA CNS metastasis program 8 July 2020
ALETA CNS metastasis program 8 July 2020Paul D. Rennert
 
Lo que un reumatólogo debe saber sobre immunoterapia del cáncer
Lo que un reumatólogo debe saber sobre immunoterapia del cáncerLo que un reumatólogo debe saber sobre immunoterapia del cáncer
Lo que un reumatólogo debe saber sobre immunoterapia del cáncerMauricio Lema
 

La actualidad más candente (20)

Artesunate improves drug resistance of lung carcinomas via regulation of mi r...
Artesunate improves drug resistance of lung carcinomas via regulation of mi r...Artesunate improves drug resistance of lung carcinomas via regulation of mi r...
Artesunate improves drug resistance of lung carcinomas via regulation of mi r...
 
2009-Hepatology
2009-Hepatology2009-Hepatology
2009-Hepatology
 
A review of micro rn as related to the occurrence, diagnosis, and prognosis o...
A review of micro rn as related to the occurrence, diagnosis, and prognosis o...A review of micro rn as related to the occurrence, diagnosis, and prognosis o...
A review of micro rn as related to the occurrence, diagnosis, and prognosis o...
 
Lnc rna neat1 is involved in temozolomide resistance by regulating mgmt in gl...
Lnc rna neat1 is involved in temozolomide resistance by regulating mgmt in gl...Lnc rna neat1 is involved in temozolomide resistance by regulating mgmt in gl...
Lnc rna neat1 is involved in temozolomide resistance by regulating mgmt in gl...
 
Im vacs 2015 rennert v2
Im vacs 2015 rennert v2Im vacs 2015 rennert v2
Im vacs 2015 rennert v2
 
Resveratrol induces apoptosis, autophagy and endoplasmic reticulum stress in ...
Resveratrol induces apoptosis, autophagy and endoplasmic reticulum stress in ...Resveratrol induces apoptosis, autophagy and endoplasmic reticulum stress in ...
Resveratrol induces apoptosis, autophagy and endoplasmic reticulum stress in ...
 
Roles of circular rn as and their interactions with micro rnas in human disor...
Roles of circular rn as and their interactions with micro rnas in human disor...Roles of circular rn as and their interactions with micro rnas in human disor...
Roles of circular rn as and their interactions with micro rnas in human disor...
 
ESMO 2020 Abstract Analysis - BioTrack
ESMO 2020 Abstract Analysis - BioTrack ESMO 2020 Abstract Analysis - BioTrack
ESMO 2020 Abstract Analysis - BioTrack
 
Io combos and the big stick
Io combos and the big stick Io combos and the big stick
Io combos and the big stick
 
Mantle Cell Lymphoma: from bench to clinic
Mantle Cell Lymphoma: from bench to clinicMantle Cell Lymphoma: from bench to clinic
Mantle Cell Lymphoma: from bench to clinic
 
FISH IN MYELOMA
 FISH IN MYELOMA FISH IN MYELOMA
FISH IN MYELOMA
 
CAR-T CELLS IN SOLID TUMORS
CAR-T CELLS IN SOLID TUMORSCAR-T CELLS IN SOLID TUMORS
CAR-T CELLS IN SOLID TUMORS
 
Next-generation Sequencing in Acute Myeloid Leukemia
Next-generation Sequencing in Acute Myeloid LeukemiaNext-generation Sequencing in Acute Myeloid Leukemia
Next-generation Sequencing in Acute Myeloid Leukemia
 
Epigenetic regulation of cardiogenesis
Epigenetic regulation of cardiogenesisEpigenetic regulation of cardiogenesis
Epigenetic regulation of cardiogenesis
 
Mi r 449b inhibits the migration and invasion of colorectal cancer cells thro...
Mi r 449b inhibits the migration and invasion of colorectal cancer cells thro...Mi r 449b inhibits the migration and invasion of colorectal cancer cells thro...
Mi r 449b inhibits the migration and invasion of colorectal cancer cells thro...
 
3768 rennert
3768 rennert3768 rennert
3768 rennert
 
ALETA CNS metastasis program 8 July 2020
ALETA CNS metastasis program 8 July 2020ALETA CNS metastasis program 8 July 2020
ALETA CNS metastasis program 8 July 2020
 
Immune cell therapy
Immune cell therapyImmune cell therapy
Immune cell therapy
 
Oncogene1.PDF
Oncogene1.PDFOncogene1.PDF
Oncogene1.PDF
 
Lo que un reumatólogo debe saber sobre immunoterapia del cáncer
Lo que un reumatólogo debe saber sobre immunoterapia del cáncerLo que un reumatólogo debe saber sobre immunoterapia del cáncer
Lo que un reumatólogo debe saber sobre immunoterapia del cáncer
 

Destacado

L agressivite en psychanalyse (21 pages 184 ko)
L agressivite en psychanalyse (21 pages   184 ko)L agressivite en psychanalyse (21 pages   184 ko)
L agressivite en psychanalyse (21 pages 184 ko)Elsa von Licy
 
Recent advances in colorectal carcinoma
Recent advances in colorectal carcinomaRecent advances in colorectal carcinoma
Recent advances in colorectal carcinomaVikash Prasad
 
Neuropsychophysiologie
NeuropsychophysiologieNeuropsychophysiologie
NeuropsychophysiologieElsa von Licy
 
Strategie Decisions Incertitude Actes conference fnege xerfi
Strategie Decisions Incertitude Actes conference fnege xerfiStrategie Decisions Incertitude Actes conference fnege xerfi
Strategie Decisions Incertitude Actes conference fnege xerfiElsa von Licy
 
Cell cycle checkpoints, apoptosis and cancer
Cell cycle checkpoints, apoptosis and cancerCell cycle checkpoints, apoptosis and cancer
Cell cycle checkpoints, apoptosis and cancerSurender Rawat
 

Destacado (6)

L agressivite en psychanalyse (21 pages 184 ko)
L agressivite en psychanalyse (21 pages   184 ko)L agressivite en psychanalyse (21 pages   184 ko)
L agressivite en psychanalyse (21 pages 184 ko)
 
Recent advances in colorectal carcinoma
Recent advances in colorectal carcinomaRecent advances in colorectal carcinoma
Recent advances in colorectal carcinoma
 
Neuropsychophysiologie
NeuropsychophysiologieNeuropsychophysiologie
Neuropsychophysiologie
 
Rainville pierre
Rainville pierreRainville pierre
Rainville pierre
 
Strategie Decisions Incertitude Actes conference fnege xerfi
Strategie Decisions Incertitude Actes conference fnege xerfiStrategie Decisions Incertitude Actes conference fnege xerfi
Strategie Decisions Incertitude Actes conference fnege xerfi
 
Cell cycle checkpoints, apoptosis and cancer
Cell cycle checkpoints, apoptosis and cancerCell cycle checkpoints, apoptosis and cancer
Cell cycle checkpoints, apoptosis and cancer
 

Similar a Cancer regulators 2013

An Overview of Prostate Cancer - Creative Biolabs
An Overview of Prostate Cancer - Creative BiolabsAn Overview of Prostate Cancer - Creative Biolabs
An Overview of Prostate Cancer - Creative BiolabsCreative-Biolabs
 
An Overview of Pancreatic Cancer - Creative Biolabs
An Overview of Pancreatic Cancer - Creative BiolabsAn Overview of Pancreatic Cancer - Creative Biolabs
An Overview of Pancreatic Cancer - Creative BiolabsCreative-Biolabs
 
An introduction to thyroid cancer
An introduction to thyroid cancerAn introduction to thyroid cancer
An introduction to thyroid cancerCreative-Biolabs
 
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'Fundación Ramón Areces
 
Ttp Lab Tech Talk 051810
Ttp Lab Tech Talk 051810Ttp Lab Tech Talk 051810
Ttp Lab Tech Talk 051810Neil Kubica
 
A novel platform for in situ, multiomic, hyper-plexed analyses of systems bio...
A novel platform for in situ, multiomic, hyper-plexed analyses of systems bio...A novel platform for in situ, multiomic, hyper-plexed analyses of systems bio...
A novel platform for in situ, multiomic, hyper-plexed analyses of systems bio...Rafael Casiano
 
Future Horizons in the Japanese Cancer Diagnostics Market: Supplier Shares an...
Future Horizons in the Japanese Cancer Diagnostics Market: Supplier Shares an...Future Horizons in the Japanese Cancer Diagnostics Market: Supplier Shares an...
Future Horizons in the Japanese Cancer Diagnostics Market: Supplier Shares an...ReportsnReports
 
A Sub-network of Signaling Protein Complexes in AA May Provide New Molecular ...
A Sub-network of Signaling Protein Complexes in AA May Provide New Molecular ...A Sub-network of Signaling Protein Complexes in AA May Provide New Molecular ...
A Sub-network of Signaling Protein Complexes in AA May Provide New Molecular ...National Alopecia Areata Foundation
 
Future Horizons in the UK Cancer Diagnostics Market: Supplier Shares and Sale...
Future Horizons in the UK Cancer Diagnostics Market: Supplier Shares and Sale...Future Horizons in the UK Cancer Diagnostics Market: Supplier Shares and Sale...
Future Horizons in the UK Cancer Diagnostics Market: Supplier Shares and Sale...ReportsnReports
 
BioMAP<sup>®</sup> Primary Human Cell-Based Systems for Drug Discovery
BioMAP<sup>®</sup> Primary Human Cell-Based Systems for Drug DiscoveryBioMAP<sup>®</sup> Primary Human Cell-Based Systems for Drug Discovery
BioMAP<sup>®</sup> Primary Human Cell-Based Systems for Drug DiscoveryBioMAP® Systems
 
Diagnostic tools in oncology
Diagnostic tools in oncologyDiagnostic tools in oncology
Diagnostic tools in oncologyMohammed Fathy
 
Пятницкий М.А. Подбор персонализированной противоопухолевой терапии путем сис...
Пятницкий М.А. Подбор персонализированной противоопухолевой терапии путем сис...Пятницкий М.А. Подбор персонализированной противоопухолевой терапии путем сис...
Пятницкий М.А. Подбор персонализированной противоопухолевой терапии путем сис...bigdatabm
 

Similar a Cancer regulators 2013 (20)

Dr. Subha Madhavan: G-DOC – Enabling Systems Medicine through Innovations in ...
Dr. Subha Madhavan: G-DOC – Enabling Systems Medicine through Innovations in ...Dr. Subha Madhavan: G-DOC – Enabling Systems Medicine through Innovations in ...
Dr. Subha Madhavan: G-DOC – Enabling Systems Medicine through Innovations in ...
 
An Overview of Prostate Cancer - Creative Biolabs
An Overview of Prostate Cancer - Creative BiolabsAn Overview of Prostate Cancer - Creative Biolabs
An Overview of Prostate Cancer - Creative Biolabs
 
An Overview of Pancreatic Cancer - Creative Biolabs
An Overview of Pancreatic Cancer - Creative BiolabsAn Overview of Pancreatic Cancer - Creative Biolabs
An Overview of Pancreatic Cancer - Creative Biolabs
 
An introduction to thyroid cancer
An introduction to thyroid cancerAn introduction to thyroid cancer
An introduction to thyroid cancer
 
Making the TRK to Precision Medicine in Cancer: The Promise of Targeting TRK ...
Making the TRK to Precision Medicine in Cancer: The Promise of Targeting TRK ...Making the TRK to Precision Medicine in Cancer: The Promise of Targeting TRK ...
Making the TRK to Precision Medicine in Cancer: The Promise of Targeting TRK ...
 
Emt and ecm 2013
Emt and ecm 2013Emt and ecm 2013
Emt and ecm 2013
 
The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to ...
The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to ...The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to ...
The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to ...
 
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
 
Ttp Lab Tech Talk 051810
Ttp Lab Tech Talk 051810Ttp Lab Tech Talk 051810
Ttp Lab Tech Talk 051810
 
JBC2
JBC2JBC2
JBC2
 
A novel platform for in situ, multiomic, hyper-plexed analyses of systems bio...
A novel platform for in situ, multiomic, hyper-plexed analyses of systems bio...A novel platform for in situ, multiomic, hyper-plexed analyses of systems bio...
A novel platform for in situ, multiomic, hyper-plexed analyses of systems bio...
 
Future Horizons in the Japanese Cancer Diagnostics Market: Supplier Shares an...
Future Horizons in the Japanese Cancer Diagnostics Market: Supplier Shares an...Future Horizons in the Japanese Cancer Diagnostics Market: Supplier Shares an...
Future Horizons in the Japanese Cancer Diagnostics Market: Supplier Shares an...
 
A Sub-network of Signaling Protein Complexes in AA May Provide New Molecular ...
A Sub-network of Signaling Protein Complexes in AA May Provide New Molecular ...A Sub-network of Signaling Protein Complexes in AA May Provide New Molecular ...
A Sub-network of Signaling Protein Complexes in AA May Provide New Molecular ...
 
The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From ...
The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From ...The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From ...
The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From ...
 
The Phantom Menace
The Phantom MenaceThe Phantom Menace
The Phantom Menace
 
Tocc ancer currentnemergingcancerdiag
Tocc ancer currentnemergingcancerdiagTocc ancer currentnemergingcancerdiag
Tocc ancer currentnemergingcancerdiag
 
Future Horizons in the UK Cancer Diagnostics Market: Supplier Shares and Sale...
Future Horizons in the UK Cancer Diagnostics Market: Supplier Shares and Sale...Future Horizons in the UK Cancer Diagnostics Market: Supplier Shares and Sale...
Future Horizons in the UK Cancer Diagnostics Market: Supplier Shares and Sale...
 
BioMAP<sup>®</sup> Primary Human Cell-Based Systems for Drug Discovery
BioMAP<sup>®</sup> Primary Human Cell-Based Systems for Drug DiscoveryBioMAP<sup>®</sup> Primary Human Cell-Based Systems for Drug Discovery
BioMAP<sup>®</sup> Primary Human Cell-Based Systems for Drug Discovery
 
Diagnostic tools in oncology
Diagnostic tools in oncologyDiagnostic tools in oncology
Diagnostic tools in oncology
 
Пятницкий М.А. Подбор персонализированной противоопухолевой терапии путем сис...
Пятницкий М.А. Подбор персонализированной противоопухолевой терапии путем сис...Пятницкий М.А. Подбор персонализированной противоопухолевой терапии путем сис...
Пятницкий М.А. Подбор персонализированной противоопухолевой терапии путем сис...
 

Más de Elsa von Licy

Styles of Scientific Reasoning, Scientific Practices and Argument in Science ...
Styles of Scientific Reasoning, Scientific Practices and Argument in Science ...Styles of Scientific Reasoning, Scientific Practices and Argument in Science ...
Styles of Scientific Reasoning, Scientific Practices and Argument in Science ...Elsa von Licy
 
C1 clef pour_la_neuro
C1 clef pour_la_neuroC1 clef pour_la_neuro
C1 clef pour_la_neuroElsa von Licy
 
Vuillez jean philippe_p01
Vuillez jean philippe_p01Vuillez jean philippe_p01
Vuillez jean philippe_p01Elsa von Licy
 
Spr ue3.1 poly cours et exercices
Spr ue3.1   poly cours et exercicesSpr ue3.1   poly cours et exercices
Spr ue3.1 poly cours et exercicesElsa von Licy
 
Plan de cours all l1 l2l3m1m2 p
Plan de cours all l1 l2l3m1m2 pPlan de cours all l1 l2l3m1m2 p
Plan de cours all l1 l2l3m1m2 pElsa von Licy
 
Bioph pharm 1an-viscosit-des_liquides_et_des_solutions
Bioph pharm 1an-viscosit-des_liquides_et_des_solutionsBioph pharm 1an-viscosit-des_liquides_et_des_solutions
Bioph pharm 1an-viscosit-des_liquides_et_des_solutionsElsa von Licy
 
Poly histologie-et-embryologie-medicales
Poly histologie-et-embryologie-medicalesPoly histologie-et-embryologie-medicales
Poly histologie-et-embryologie-medicalesElsa von Licy
 
Methodes travail etudiants
Methodes travail etudiantsMethodes travail etudiants
Methodes travail etudiantsElsa von Licy
 
Atelier.etude.efficace
Atelier.etude.efficaceAtelier.etude.efficace
Atelier.etude.efficaceElsa von Licy
 
There is no_such_thing_as_a_social_science_intro
There is no_such_thing_as_a_social_science_introThere is no_such_thing_as_a_social_science_intro
There is no_such_thing_as_a_social_science_introElsa von Licy
 
Principles and neurobiological_correlates_of.5
Principles and neurobiological_correlates_of.5Principles and neurobiological_correlates_of.5
Principles and neurobiological_correlates_of.5Elsa von Licy
 
A short history of man — progress and decline
A short history of man — progress and declineA short history of man — progress and decline
A short history of man — progress and declineElsa von Licy
 

Más de Elsa von Licy (20)

Styles of Scientific Reasoning, Scientific Practices and Argument in Science ...
Styles of Scientific Reasoning, Scientific Practices and Argument in Science ...Styles of Scientific Reasoning, Scientific Practices and Argument in Science ...
Styles of Scientific Reasoning, Scientific Practices and Argument in Science ...
 
C1 clef pour_la_neuro
C1 clef pour_la_neuroC1 clef pour_la_neuro
C1 clef pour_la_neuro
 
Hemostase polycop
Hemostase polycopHemostase polycop
Hemostase polycop
 
Antiphilos
AntiphilosAntiphilos
Antiphilos
 
Vuillez jean philippe_p01
Vuillez jean philippe_p01Vuillez jean philippe_p01
Vuillez jean philippe_p01
 
Spr ue3.1 poly cours et exercices
Spr ue3.1   poly cours et exercicesSpr ue3.1   poly cours et exercices
Spr ue3.1 poly cours et exercices
 
Plan de cours all l1 l2l3m1m2 p
Plan de cours all l1 l2l3m1m2 pPlan de cours all l1 l2l3m1m2 p
Plan de cours all l1 l2l3m1m2 p
 
M2 bmc2007 cours01
M2 bmc2007 cours01M2 bmc2007 cours01
M2 bmc2007 cours01
 
Feuilletage
FeuilletageFeuilletage
Feuilletage
 
Chapitre 1
Chapitre 1Chapitre 1
Chapitre 1
 
Biophy
BiophyBiophy
Biophy
 
Bioph pharm 1an-viscosit-des_liquides_et_des_solutions
Bioph pharm 1an-viscosit-des_liquides_et_des_solutionsBioph pharm 1an-viscosit-des_liquides_et_des_solutions
Bioph pharm 1an-viscosit-des_liquides_et_des_solutions
 
Poly histologie-et-embryologie-medicales
Poly histologie-et-embryologie-medicalesPoly histologie-et-embryologie-medicales
Poly histologie-et-embryologie-medicales
 
Methodes travail etudiants
Methodes travail etudiantsMethodes travail etudiants
Methodes travail etudiants
 
Atelier.etude.efficace
Atelier.etude.efficaceAtelier.etude.efficace
Atelier.etude.efficace
 
There is no_such_thing_as_a_social_science_intro
There is no_such_thing_as_a_social_science_introThere is no_such_thing_as_a_social_science_intro
There is no_such_thing_as_a_social_science_intro
 
Prolegomena 4 0
Prolegomena 4 0Prolegomena 4 0
Prolegomena 4 0
 
Swa 2015 final
Swa 2015 finalSwa 2015 final
Swa 2015 final
 
Principles and neurobiological_correlates_of.5
Principles and neurobiological_correlates_of.5Principles and neurobiological_correlates_of.5
Principles and neurobiological_correlates_of.5
 
A short history of man — progress and decline
A short history of man — progress and declineA short history of man — progress and decline
A short history of man — progress and decline
 

Cancer regulators 2013

  • 1. Identify the Key Players and Their Regulators in Major Cancer Types Jesse Liang, Ph.D. 1 Sample & Assay Technologies
  • 2. 8 Hallmarks of Cancer . . . . . . . . . The 8 Hallmarks of Cancer (Cell, March 2011): 1. Sustaining proliferative signaling 2. Evading growth suppressors 3. Resisting cell death 4. Enabling replicative immortality 5. Inducing angiogenesis 6. Activating invasion and metastasis 7. Reprogramming energy metabolism 8. Escaping immune destruction -2- Sample & Assay Technologies
  • 3. Corresponding PCR Arrays to Study These Hallmarks 1. Cell Cycle 2. Apoptosis 3. Cell Death Pathway Finder 4. Telomeres and Telomerases 5. Angiogenesis 6. Extracellular Matrix (ECM) and Adhesion Molecules 7. EMT (Epithelial-Mesenchymal Transition) 8. Tumor Metastasis 9. Cell Motility 10. Energy Metabolism 11. Innate and Adaptive Immune Response 12. Cancer Pathway Finder . . . . . . . . . . . . . http://www.sabiosciences.com/ArrayList.php -3- Sample & Assay Technologies
  • 4. Profile Key Gene Expressions – Using RT2 Profiler PCR Array 84 Pathway-Specific Genes of Interest 5 Housekeeping Genes Genomic DNA Contamination Control Reverse Transcription Controls (RTC) Positive PCR Controls (PPC) -4- Sample & Assay Technologies
  • 5. Simple Workflow of PCR Arrays cDNA Synthesis (kit) 45 minutes Load Plates (Use 8-Channel Pipettors) 2 minutes Run 40 cycle qPCR Program 2 to 2.5 hours compatible with all major real-time PCR instruments Upload and Analyze Data 15 minutes -5- Sample & Assay Technologies
  • 6. Identify the Key Genetic Players in Breast Cancer . Breast Cancer PCR Array http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-131A.html Breast cancer can be classified into normal breast-like, luminal, HER2-like, and basallike (also inaccurately called triple-negative) tumors. . Tumor Classification Markers: Luminal: ESR1 (ERa), FOXA1, GATA3, KRT8, KRT18, SLC39A6, TFF3, XBP1. HER2-like: ERBB2 (HER2), GRB7. Basal-like / Triple Negative: BIRC5, EGFR, KRT5, NOTCH1. Metastasis to Lung: ID1, MMP2 (Gelatinase A), PTGS2 (COX2). . Signal Transduction: Steroid Receptor-Mediated: AR, BRCA1, CCNE1, CTNNB1, ESR1 (ERa), ESR2 (ERß), IGF1, KRT19, PGR, RB1. Hedgehog: BCL2, CCND1, GLI1, SNAI2. Glucocorticoid: IGFBP3, NME1 (NM23A), NR3C1 (GRL). Classical WNT: APC, CCND1, CTNNB1, SFRP1. PI3K/AKT: AKT1, ERBB2 (HER2), IGF1, IGF1R, PTEN. NOTCH: BIRC5, NOTCH1. MAPK: MAPK1 (ERK2), MAPK3 (ERK1), MAPK8 (JNK1), TP73. . -6- Sample & Assay Technologies
  • 7. Breast Cancer Subtypes Subtype These tumors tend to be Prevalence Luminal A ER+ and/or PR+, HER2-, low Ki67 42-59% Luminal B ER+ and/or PR+, HER2+ (or HER2with high Ki67) 6-19% Triple negative/basal-like ER-, PR-, HER2-, cytokeratin 5/6 + and/or HER1(EGFR)+ 14-20% HER2+ ER-, PR-, HER2+ 7-12% -7- Sample & Assay Technologies
  • 8. Identify the Key Genetic Players in Lung Cancer . Lung Cancer PCR Array http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-134A.html non-small-cell lung carcinoma (NSCLC) and small-cell lung carcinoma (SCLC) . Differentially Methylated Promoters: APBA1, APC, CADM1, CDH1, CDH13, CDKN1C, CDKN2A, CDKN2B, CXCL12, CYP1B1, DLC1, FHIT, MGMT, MLH1, MTHFR, OPCML, PRDM2, RASSF1, RASSF2, SFRP1, TCF21 Metastatic Potential: ANXA5, DUSP6, ERBB3, HGF, HMMR, IRF4, LCK, MET, MMD, NF1, STAT1, STAT2 . . Differentially Expressed Genes in Adenocarcinoma (AC) Versus Squamous Cell Carcinoma (SCC): Higher in AC than in SCC: CLCA2, DSG3, KRT5, KRT14, SPRR1A Higher in SCC than in AC: AGR2, LGSN, NKX2-1, SFTA3, SPINK1 . . Up-Regulated in Lung Cancer: CEACAM5, COL11A1, CP, CXCL13, GREM1, MKI67, MMP1, MMP12, SPINK1, SPP1, TOP2A, TOX3 Down-Regulated in Lung Cancer: AGER, CA4, CLDN18, CLIC5, FABP4, GPM6A, SCGB1A1, SFTPC, SOSTDC1, WIF1 . . -8- Sample & Assay Technologies
  • 9. Identify the Key Genetic Players in Prostate Cancer . Prostate Cancer PCR Array http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-135A.html . Differentially Methylated Promoters: APC, AR, CAV1, CCNA1, CDH1, CDKN2A, DKK3, DLC1, EDNRB, GPX3, GSTP1, MGMT, MSX1, PDLIM4, PTGS2, RARB, RASSF1, SFRP1, SLC5A8, TIMP2, TNFRSF10D, ZNF185 . Up-Regulated in Prostate Cancer: ARNTL, CAMSAP1, DDX11, ECT2, ETV1, HAL, IGFBP5, KLK3, MTO1, PDPK1, RBM39, SOCS3, SOX4, SUPT7L . Down-Regulated in Prostate Cancer: CCND2, CLN3, GCA, IGF1, LGALS4, LOXL1, PPP2R1B, SFRP1, SLC5A8, TFPI2, USP5 . Metastatic Potential: CREB1, INTS6, KLHL13, MAX, NDRG3, PES1, SEPT7, SCAF11 . Androgen Signaling: AR, CAV1, CCND1, DAXX, EGFR, FOXO1, GNRH1, IGF1, IL6, NFKB1, NRIP1, PTEN, SHBG, TGFB1I1, TIMP2, TIMP3, VEGFA . -9- Sample & Assay Technologies
  • 10. Identify the Key Genetic Players in Liver Cancer . Liver Cancer (HCC) PCR Array http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-133A.html . Genes Up-Regulated During HCC: BCL2, BIRC5, CCND1, CFLAR (CASPER), FZD7, IGF2, IRS1, LEF1, MCL1, MET, NFKB1, PIN1, PTK2, RAC1, RHOA, SMAD7, STAT3, TCF4, TGFA, TGFB1, TNFSF10 (TRAIL), XIAP . Genes Down-Regulated During HCC: BAX, BID, CASP8 (FLICE), CDKN1A (p21CIP1/WAF1), CDKN2A (p16INK4), DLC1, FADD, FAS (TNFRSF6), HHIP, IGFBP1, IGFBP3, ITGB1, PTEN, RB1, SMAD4, SOCS1, SOCS3,TGFBR2, TNFRSF10B (DR5) . Signal Transduction: Classical WNT: CCND1, CDKN2A (p16INK4), CTNNB1, FZD7, LEF1, MTDH, PIN1, RB1, SFRP2, TCF4. TGFß: SMAD4, SMAD7, TGFB1, TGFBR2 PI3K/AKT: AKT1, IRS1, PTEN. IGF/IGFR: IGF2, IGFBP1, IGFBP3, IRS1 Hippo: YAP1 (Yes-Associated Protein (YAP) is a potent oncogenic driver and an . independent prognostic risk factor of HCC) Ras/Raf/MEK/ERK: CDKN1A (p21CIP1/WAF1), CDKN2A (p16INK4), DLC1, HRAS, NRAS, RAC1, RASSF1, RB1, RHOA, TP53 EGFR: ADAM17 (CD156B), CDH13, EGF, EGFR, TGFA, TGFB1 MET/HGF: MET, HGF Small GTPase-Mediated: CDH13, CDKN1A (p21CIP1/WAF1), CDKN2A (p16INK4), DAB2IP, DLC1, HRAS, NRAS, RAC1, RASSF1, RB1, RELN, RHOA, TP53 - 10 - Sample & Assay Technologies
  • 11. Identify the Key Genetic Players in Leukemia . Leukemia PCR Array http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-137A.html Clinical and pathological subtypes of leukemia define both its onset (acute or chronic) and the affected blood cell type (lymphoblastic/lymphocytic or myeloid/myelogenous). . . Differentially Methylated Promoters: APAF1, CADM1, CDH1, CDH13, CDKN1A, CDKN1B, CDKN1C, CDKN2B, DAPK1, DKK3, DLC1, EGR3, HIC1, JUNB, MEIS1, MLH1, NPM1, PTEN, SFRP2, SFRP4, SFRP5, SOCS1, TP53, WIF1 BCR-ABL Pathway: ABL1, BCR, GRB2, JAK2, SHC1, STAT3, STAT5A, STAT5B JAK-STAT Signaling: AKT1, CSF3, IFNA1, IL4, IL6, JAK2, STAT1, STAT3, STAT5A, STAT5B, SOCS1 Hemopoiesis: BCL2, CSF3, CTNNB1, IL4, JAK2, LMO2, PML, RUNX1, STAT5A, STAT5B, TAL1, TP53 Myeloid Cell Differentiation: CTNNB1, FOXO3, IL4, JUN, LMO2, RUNX1, SPI1, STAT5A, STAT5B, TAL1 Immune System Development: BCL2, CSF3, CTNNB1, IL4, JAK2, LMO2, MLH1, PML, RUNX1, STAT5A, STAT5B, TAL1, TLX1, TP53 Lymphocyte Proliferation/Differentiation: BCL2, CSF3, CTNNB1, IL4, IL6, STAT5A, STAT5B Cytokines & Chemokines: CCL3, CSF3, CXCL10, IFNA1, IL1R1, IL4, IL6, IL8, IL10, IL12A Malignancy: BAALC, BMPR1B, BTG3, CD34, CDC42EP3, CTGF, GAS2L3, MN1, NR4A3, RGS12 Leukemia Therapeutic Targets: AKT1, ALOX5, BCL2, CTNNB1, FGR, FOXO3, HCK, HDAC1, HSP90AA1, IFNA1, JAK2, MCL1, MERTK, MTOR, PML, PRKCB, RAC2, SMO Leukemia Stem Cell Transcriptional Regulators: CEBPB, GATA1, IKZF3, JUN, LMO1, LMO2, LYL1, MEIS1, NFKB1, RUNX1, RUNX2, RUNX3, SPI1, STAT1, STAT3, STAT5A, TAL1, TLX1, TLX3 . . . . . . . . . . . - 11 - Sample & Assay Technologies
  • 12. Identify the Key Genetic Players in Lymphoma Lymphoma PCR Array . . . . . . . . . . . . . http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-139A.html Differentially Methylated Promoters: AFF1, ATM, CADM1, CCND1, CDH1, CDH13, CDKN1C, CDKN2B, CDKN2C, DAPK1, DLC1, FHIT, GSTP1, HIC1, HRK, ID4, LRP1B, MLH1, MYOD1, RASSF1, RBP1, SLC19A1, TIMP2, TIMP3 DLBCL (Diffuse Large B-cell Lymphoma) Survival: ASB13, BCL6, ITPKB, LMO2, LRMP, MYBL1, PAG1, PTK2, TTC9, VGLL4 Follicular Lymphoma Survival: C1QA, C4A, CCR1, F8, FCGR1A, FLT3LG, STAT4, TLR5, TNFRSF1B, TNFSF13B Lymphoma Therapeutic Targets: BCL6, BIRC5, BTK, CD22, CD40, CD80, CXCR4, FCGR1A, HSP90AA1, MCL1, MS4A1, MTOR, NOTCH1, PARP1, PTK2, SRC, SYK, TGFB1, TNFSF13B Inflammatory Response: C1QA, C4A, CCR1, CD40, CD40LG, CSF3, CXCR4, F8, IL6, NFKB1, TGFB1, TLR5, TNF, TNFRSF1B Immune System Process: BCL6, C1QA, C4A, CADM1, CD2, CD4, CD40, CD5, CD79A, CD80, FCER2, IFNG, IL2, IL6, ITPKB, PDLIM7, PTPRC, SYK, TGFB1, TNFSF13B T Cell Differentiation: BCL2, CD3D, CD4, CD8A, ITPKB, IL2, PTPRC, SYK, TGFB1, TP53 Cell Adhesion: BCL2, CADM1, CCR1, CD2, CD22, CD34, CD4, CD40LG, CD8A, CDH1, CDH13, DLC1, F8, IL2, NCAM1, PTPRC, SRC, SYK, TNF Cell Cycle: ATM, BCL2, BIRC5, CCND1, CDKN1C, CDKN2B, CDKN2C, ID4, IFNG, MKI67, MLH1, MYC, RASSF1, TGFB1, TP53 PI3K/AKT Signaling: ALK, BCL2, BTK, CCND1, CCR1, CD2, CD4, CD40, CD40LG, CSF3, CXCR4, HSP90AA1, IL2, IL6, MTOR, PTK2, SYK, TGFB1, TIMP2, TIMP3, TNFRSF1B, TNFSF13B, TP53 Gene Fusion: ALK, MME DNA Repair: DNTT - 12 - Sample & Assay Technologies
  • 13. Methylation PCR Arrays . . 1. DNA Digestion Genomic DNA sample is aliquoted into four equal portions: a. Mock Digest (Mo) No enzymes are added in this reaction. The product of the mock digestion represents the total amount of input DNA for real-time PCR detection. b. Methylation Sensitive Digest (Ms) Cleavage with a methylation-sensitive enzyme will digest unmethylated and partially methylated DNA. The remaining (hyper)-methylated DNA will be detected by real-time PCR. c. Methylation Dependent Digest (Md) Cleavage with a methylation-dependent enzyme will preferentially digest methylated DNA. The remaining unmethylated DNA will be detected by realtime PCR. d. Double Digest (Msd) Both enzymes are added in the double digest, and all DNA molecules (both methylated and unmethylated) will be digested. This reaction measures the background and the fraction of input DNA refractory to enzyme digestion. . . . . . . . . . . . . 2. Real-Time PCR 3. Data Analysis We provide user-friendly free online data analysis tool. - 13 - Sample & Assay Technologies
  • 14. What Methylation PCR Array Offers – a Quick Screening Tool . What Does Methylation PCR Array Offer? http://www.sabiosciences.com/dna_methylation.php . . Disease or Pathway Focused: Simultaneously detect DNA methylation of 24-96 genes on a 96-well or 384-well plate. . Genome-Wide Coverage: DNA methylation analysis of any human, mouse or rat genes. You can also order individual primers for an individual gene. Ordering custom array is also welcome. . Easy, Fast & Reliable: Simple restriction enzyme digestion followed by optimized qPCR. No bisulfite conversion, cloning or sequencing. - 14 - Sample & Assay Technologies
  • 15. Identify the Key Epigenetic Players in Breast Cancer Breast Cancer Methylation PCR Array: http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-011A.html Cell Cycle, Growth, Differentiation & Development: BRCA1, CCNA1, CCND2, CDKN1C, CDKN2A (p14ARF), CDKN2A (p16), SFN (14-3-3 sigma), TP73 Cell Adhesion: CDH1, CDH13 Transcription Factors: CDKN2A (p14ARF), ESR1, HIC1, PRDM2, RASSF1, TP73 Hormone Receptors: ESR1 Drug Metabolism: GSTP1 Apoptosis & Anti-Apoptosis: CDKN2A (p14ARF), CDKN2A (p16), PYCARD, TNFRSF10C, TNFRSF10D, TP73 DNA Methylation: MGMT, PRDM2 Phosphatases: PTEN Prostaglandin-Endoperoxide Synthase: PTGS2 Extracellular Matrix Molecules: ADAM23, SLIT2, THBS1 Proteases & Protease Inhibitors: DAM23, THBS1 Ras Associated Protein Superfamily: RASSF1 - 15 - Sample & Assay Technologies
  • 16. Identify the Key Epigenetic Players in Lung Cancer Lung Cancer Methylation PCR Array: http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-041A.html . Apoptosis & Anti-Apoptosis: APC, CADM1 (TSLC1), CDKN1C (p57Kip2), CDKN2A (p14ARF), CDKN2B (p15INK4b), FHIT Cell Adhesion & Migration: APC, CADM1 (TSLC1), CDH1, CDH13, DLC1, OPCML (aOBCAM) Cell Cycle, Growth, Differentiation & Development: APC, CADM1 (TSLC1), CDKN1C (p57Kip2), CDKN2A (p14ARF), CDKN2B (p15INK4b), DLC1, FHIT, MLH1, PRDM2 (RIZ1), RASSF1, RASSF2, TCF21 Chemokine: CXCL12 Neuronal Adaptor Protein: APBA1 (MINT1) DNA Damage Repair: APC, MLH1, RASSF1 DNA Methyl Transferase: MGMT (AGT), PRDM2 Drug Metabolism: CYP1B1 Oncogene: PAX5 Histidine Triad Gene Family: FHIT miRNA Genes: has-let-7a, hsa-miR-124 One Carbon Unit Metabolism: MTHFR Transcription Factors: PAX5, PRDM2 (RIZ1), TCF21 Tumor Suppressor Gene Candidates: APC, CDKN1C (p57Kip2), CDKN2A (p14ARF), CDKN2B (p15INK4b), MLH1, RASSF1, RASSF2 WNT Signaling: APC, SFRP1 . . - 16 - Sample & Assay Technologies
  • 17. Identify the Key Epigenetic Players in Prostate Cancer Prostate Cancer Methylation PCR Array: http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-051A.html . Apoptosis & Anti-Apoptosis: APC, CDKN2A (P16), TNFRSF10D Calcium Channel Signaling: EDNRB Caveolae Protein: CAV1 Cell Cycle, Growth, Differentiation & Development: APC, CCNA1, CDKN2A (P16), DLC1, RARB, RASSF1 Cell Adhesion & Migration: APC, CDH1, DLC1, OPCML (aOBCAM), TIMP2 Cytokine: TNFRSF10D Drug Metabolism: GPX3, GSTP1, SLC5A8 DNA Methyltransferase: MGMT (AGT) Extracellular Matrix Remodeling: TIMP2 Inflammation: PTGS2 (COX2) miRNA Genes: hsa-miR-34a Mitogenesis: PTGS2 (COX2) Nuclear Receptors: AR, RARB Oncogene: CAV1 Protease Inhibitor: TIMP2 Retinoid Acid Signaling: RARB Solute Carrier Family: SLC5A8 Transcription Factors and Cofactors: MSX1, PDLIM4 (RIL) Tumor Suppressor Gene Candidates: APC, CAV1, CDKN2A (P16), RASSF1, SLC5A8, ZNF185 Wnt Signaling Pathway: APC, DKK3, SFRP1 . - 17 - Sample & Assay Technologies
  • 18. Identify the Key Epigenetic Players in Liver Cancer Liver Cancer Methylation PCR Array: . http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-031A.html . Angiogenesis: EP300 Apoptosis & Anti-Apoptosis: CDKN1B, CDKN2A (P16,), FHIT, PYCARD (TMS1/ASC), TNFRSF10D Cell Adhesion & Migration: CDH1, DLC1, OPCML (aOBCAM), RELN Cell Cycle, Growth, Differentiation & Development: CCND2 (Cyclin D2), CDKN1A, CDKN1B (p27KIP1), CDKN2A (P16), DLC1, EP300, FHIT, RASSF1, WT1 Cytokine Receptor: TNFRSF10D Cytokine Signaling Inhibitor: SOCS1 DNA Damage Repair: CDKN1A, MSH2, MSH3, RASSF1 Drug Metabolism: GSTP1 Extracellular Matrix Remodeling: RELN GTPase-Activating Protein: DAB2IP Histidine Triad Gene Family: FHIT Inflammation: PYCARD (TMS1/ASC) miRNA Gene: hsa-miR-1 Oncogene: E2F1 Transcription Factors: E2F1, EP300, RUNX3, WT1, EP300 Tumor Suppressor Gene Candidates: DLEC1, CDKN1A, CDKN2A (P16), E2F1, MSH2, MSH3, RASSF1, RUNX3 Wnt Signaling Pathway: SFRP2 . - 18 - Sample & Assay Technologies
  • 19. Identify the Key Epigenetic Players in Leukemia & Lymphoma Leukemia & Lymphoma Methylation PCR Array: . http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-071A.html . Development & Differentiation: HCK, MAFB, MEN1, TP53 Cell Cycle: JUNB, MEN1, NPM1, TP53 DNA Damage & Repair: FANCC, FANCL, NPM1, PMS1, TP53 Extracellular Matrix and Adhesion: CD9, CTNNA1, SPOCK2 Growth & Proliferation: DRD2, MEN1, NPM1, SLC5A8, TP53 Signal Transduction: DRD2, EXT1, MEN1, NFATC1, NPM1, PARK2, PER2, TLE1, TP53 Transcription Factors & Co-Factors: AFF1, CEBPD, HOXA7, HOXB5, JUNB, MAFB, NFATC1, NPM1, TLE1, TP53 Other: LMNA . . . . . . . . - 19 - Sample & Assay Technologies
  • 20. Identify the Key Epigenetic Players in Other Cancers Colon Cancer: . http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-061A.html . Gastric Cancer: . http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-021A.html . Melanoma: . http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-081A.html -------------------------------------------------------------------------------------------------------------- . . EMT (Epithelial-Mesenchymal Transition): . http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-901A.html . Tumor Suppressor Genes: . http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-551A.html . Apoptosis: . http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-121A.html . Cell Cycle: . http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-201A.html . DNA Repair: . http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-421A.html . Cancer miRNA: . http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-591A.html . - 20 - Sample & Assay Technologies
  • 21. Important Note . Please Note: If you study lung cancer, for example, I greatly recommend that you use regular Lung Cancer PCR Array and Methylation Lung Cancer PCR Array to get corresponding results. This applies to other cancer types, also to apoptosis, cell cycle, DNA damage, EMT, tumor suppressors, and cancer-related miRNAs researchers. . - 21 - Sample & Assay Technologies
  • 22. Cancer Mutation PCR Arrays and Assays Custom available! We also provide over 900 individual gene assays: http://www.sabiosciences.com/mutationproductlist.php?tab=browsebygene - 22 - Sample & Assay Technologies
  • 23. Overview 45-Signaling Pathway Activity in a Cell Assay Transcription factor activity can be used as a readout for the activation status of signal transduction pathways. Therefore, the development of reliable cell-based assays to measure transcription factor activity is a crucial technology for fast and efficient global functional genomics and chemical genetics studies. . . Cignal 45-Pathway Reporter Array is a novel cell-based assay for monitoring 45 cell signaling pathways in cultured cells in a single experiment. You can observe phenotypes and quantitate as a dual-luciferase assay. http://www.sabiosciences.com/reporter_assay_product/HTML/CCA-901L.html For individual assay: http://www.sabiosciences.com/reporterproductList.php - 23 - Sample & Assay Technologies
  • 24. We Provide Service – Send Samples to Us & Receive Results! Whole Genome Illumina Gene Expression Profiling Illumina Genotyping . Pathway / Focused Panel Mutation Profiling Methylation PCR Array miRNA PCR Array . . . . . Individual Gene / Locus Mutation Detection Methylation qPCR . . . . Sample Preparation – DNA, RNA Extraction and Purification Cells, Tissue or Biofluids Fixed Tissue Small Sample . . . . http://www.sabiosciences.com/servicecore.php . - 24 - Sample & Assay Technologies
  • 25. Contact Information . . . . . Jesse Liang Email: jesse.liang@qiagen.com Technical Support: 1-888-503-3187 Email: support@sabiosciences.com Check Webinar Calendar: http://www.sabiosciences.com/seminarlist.php . - 25 - Sample & Assay Technologies